317 related articles for article (PubMed ID: 18356814)
1. Integrating the biological characteristics of oncolytic viruses and immune cells can optimize therapeutic benefits of cell-based delivery.
Thorne SH; Contag CH
Gene Ther; 2008 May; 15(10):753-8. PubMed ID: 18356814
[TBL] [Abstract][Full Text] [Related]
2. Synergistic antitumor effects of immune cell-viral biotherapy.
Thorne SH; Negrin RS; Contag CH
Science; 2006 Mar; 311(5768):1780-4. PubMed ID: 16556847
[TBL] [Abstract][Full Text] [Related]
3. A new recombinant vaccinia with targeted deletion of three viral genes: its safety and efficacy as an oncolytic virus.
Yang S; Guo ZS; O'Malley ME; Yin X; Zeh HJ; Bartlett DL
Gene Ther; 2007 Apr; 14(8):638-47. PubMed ID: 17268533
[TBL] [Abstract][Full Text] [Related]
4. Targeting cancer by transcriptional control in cancer gene therapy and viral oncolysis.
Dorer DE; Nettelbeck DM
Adv Drug Deliv Rev; 2009 Jul; 61(7-8):554-71. PubMed ID: 19394376
[TBL] [Abstract][Full Text] [Related]
5. Vaccinia virus and oncolytic virotherapy of cancer.
Thorne SH; Hwang TH; Kirn DH
Curr Opin Mol Ther; 2005 Aug; 7(4):359-65. PubMed ID: 16121702
[TBL] [Abstract][Full Text] [Related]
6. Taming the Trojan horse: optimizing dynamic carrier cell/oncolytic virus systems for cancer biotherapy.
Power AT; Bell JC
Gene Ther; 2008 May; 15(10):772-9. PubMed ID: 18369325
[TBL] [Abstract][Full Text] [Related]
7. Exploiting diversity: genetic approaches to creating highly potent and efficacious oncolytic viruses.
Bauzon M; Hermiston TW
Curr Opin Mol Ther; 2008 Aug; 10(4):350-5. PubMed ID: 18683099
[TBL] [Abstract][Full Text] [Related]
8. Advances in oncolytic viral therapy.
Woo Y; Adusumilli PS; Fong Y
Curr Opin Investig Drugs; 2006 Jun; 7(6):549-59. PubMed ID: 16784026
[TBL] [Abstract][Full Text] [Related]
9. Potential of tumour cells for delivering oncolytic viruses.
Raykov Z; Rommelaere J
Gene Ther; 2008 May; 15(10):704-10. PubMed ID: 18356816
[TBL] [Abstract][Full Text] [Related]
10. Virus combinations and chemotherapy for the treatment of human cancers.
Kumar S; Gao L; Yeagy B; Reid T
Curr Opin Mol Ther; 2008 Aug; 10(4):371-9. PubMed ID: 18683102
[TBL] [Abstract][Full Text] [Related]
11. The emergence of combinatorial strategies in the development of RNA oncolytic virus therapies.
Nguyen TL; Tumilasci VF; Singhroy D; Arguello M; Hiscott J
Cell Microbiol; 2009 Jun; 11(6):889-97. PubMed ID: 19388908
[TBL] [Abstract][Full Text] [Related]
12. Enhancing poxvirus oncolytic effects through increased spread and immune evasion.
Kirn DH; Wang Y; Liang W; Contag CH; Thorne SH
Cancer Res; 2008 Apr; 68(7):2071-5. PubMed ID: 18381410
[TBL] [Abstract][Full Text] [Related]
13. Cell carriers to deliver oncolytic viruses to sites of myeloma tumor growth.
Munguia A; Ota T; Miest T; Russell SJ
Gene Ther; 2008 May; 15(10):797-806. PubMed ID: 18356812
[TBL] [Abstract][Full Text] [Related]
14. Natural and genetically engineered viral agents for oncolysis and gene therapy of human cancers.
Sinkovics JG; Horvath JC
Arch Immunol Ther Exp (Warsz); 2008 Dec; 56 Suppl 1():3s-59s. PubMed ID: 19104757
[TBL] [Abstract][Full Text] [Related]
15. Generation of a recombinant oncolytic Newcastle disease virus and expression of a full IgG antibody from two transgenes.
Pühler F; Willuda J; Puhlmann J; Mumberg D; Römer-Oberdörfer A; Beier R
Gene Ther; 2008 Mar; 15(5):371-83. PubMed ID: 18200068
[TBL] [Abstract][Full Text] [Related]
16. Viral gene therapy strategies: from basic science to clinical application.
Young LS; Searle PF; Onion D; Mautner V
J Pathol; 2006 Jan; 208(2):299-318. PubMed ID: 16362990
[TBL] [Abstract][Full Text] [Related]
17. Gene therapy progress and prospects cancer: oncolytic viruses.
Liu TC; Kirn D
Gene Ther; 2008 Jun; 15(12):877-84. PubMed ID: 18418413
[TBL] [Abstract][Full Text] [Related]
18. Efficacy of systemically administered oncolytic vaccinia virotherapy for malignant gliomas is enhanced by combination therapy with rapamycin or cyclophosphamide.
Lun XQ; Jang JH; Tang N; Deng H; Head R; Bell JC; Stojdl DF; Nutt CL; Senger DL; Forsyth PA; McCart JA
Clin Cancer Res; 2009 Apr; 15(8):2777-88. PubMed ID: 19351762
[TBL] [Abstract][Full Text] [Related]
19. Synergistic anti-tumor effects between oncolytic vaccinia virus and paclitaxel are mediated by the IFN response and HMGB1.
Huang B; Sikorski R; Kirn DH; Thorne SH
Gene Ther; 2011 Feb; 18(2):164-72. PubMed ID: 20739958
[TBL] [Abstract][Full Text] [Related]
20. Endothelial progenitor cells as cellular vehicles to deliver oncolytic virus therapies to metastatic tumors: the "Trojan horse" approach.
Deng W; Jia J
Med Hypotheses; 2008; 70(4):842-4. PubMed ID: 17869010
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
